Treatment of agitation in Alzheimer disease, text messaging for CV risk modification, a newly approved PCSK9 inhibitor for dyslipidemia, and more.
Sep 22, 2015
8:43
Episode Description
Editor's Audio Summary by Howard Bauchner, MD, Editor in Chief of JAMA, the Journal of the American Medical Association, for the September 22/29, 2015 issue
Proudly Supported by
